DUSP8 and cancer: Moreover, DUSP8 restoration increased sensitivity of GdEC#1 to ralimetinib treatment whereas GdEC#1 sh-DUSP8-GFP showed a decreased sensitivity confirming the critical role of DUSP8 in determining sensitivity to cancer therapeutics [36].